Cytokine Concentration Correlates with Diabetic Nephropathy
By LabMedica International staff writers Posted on 01 Mar 2017 |
Image: The BN Prospec System for particle enhanced immuoturbidimetric methodology (Photo courtesy of Siemens Healthineers).
Diabetic nephropathy (DN) is a major microvascular complication of diabetes mellitus, and it is the leading cause of end-stage renal disease and inflammation plays some important roles in the pathogenesis of DN.
Interleukin-19 (IL-19) is a newly discovered cytokine belonging to the Interleukin-10 (IL-10) family. IL-19 cytokines have indispensable functions in many inflammatory processes and also can induce the angiogenic potential of endothelial cells.
Scientists at the Jiangsu University School of Clinical Medicine selected 200 patients with type 2 diabetes mellitus (T2DM) (109 males and 91 females, age 60 ± 10.3 years) from July to December in 2015. According to urinary albumin excretion rate (UAE), the patients were divided into three groups: 102 patients with T2DM with normoalbuminuria, (UAE < 30 mg/24 hours), 72 T2DM patients with microalbuminuria (UAE: 30 to 300 mg/24 hours) and 26 T2DM patients with macroalbuminuria (UAE ≥300 mg/24 hours). There were 50 healthy blood donors enrolled for the control group.
All subjects were assessed for: IL-19, High-sensitivity C-reactive protein (Hs-CRP), Cystatin C, urinary albumin excretion rate (UAE) and glycosylated hemoglobin A1C (HbA1c). IL-19 was determined by the enzyme-linked immunosorbent assay (ELISA) kits. Urinary albumin and Hs-CRP concentrations were assessed using the particle enhanced immuoturbidimetric method. HbA1c was measured by liquid chromatography. Fasting plasma glucose (FPG), total cholesterol (TC), high-density lipoprotein (HDL-C) and LDL cholesterol (LDL-C) were measured by enzymatically.
The team found that the serum IL-19 levels in DN patients were found to be significantly higher compared to controls. IL-19 levels were significantly positively correlated with Hs-CRP, Cystatin C, UAE and HbA1c. In multivariable logistic regression analysis, IL-19 levels (95% CI, 20.1 to 62.9) alone showed a significant positive association with DN even after adjusting for age, gender, hypertension, and blood fat. The HbA1c in the microalbuminuric/macroalbuminuric diabetic group were significantly increased compared to normoalbuminuric and control groups.
The authors concluded that that IL-19 levels was significantly elevated in the patients with diabetic nephropathy and was associated with Hs-CRP, Cystatin C, UAE and HbA1c. The results suggest that IL-19 has an important role in the acceleration of glomerular injury in addition to its inflammatory effect on this pathophysiology, and provide further insights into the understanding of IL-19 as the possible effectiveness of anti-inflammatory therapy for DN treatment and prevention. The study was published on February 15, 2017, in the journal BMC Nephrology.
Interleukin-19 (IL-19) is a newly discovered cytokine belonging to the Interleukin-10 (IL-10) family. IL-19 cytokines have indispensable functions in many inflammatory processes and also can induce the angiogenic potential of endothelial cells.
Scientists at the Jiangsu University School of Clinical Medicine selected 200 patients with type 2 diabetes mellitus (T2DM) (109 males and 91 females, age 60 ± 10.3 years) from July to December in 2015. According to urinary albumin excretion rate (UAE), the patients were divided into three groups: 102 patients with T2DM with normoalbuminuria, (UAE < 30 mg/24 hours), 72 T2DM patients with microalbuminuria (UAE: 30 to 300 mg/24 hours) and 26 T2DM patients with macroalbuminuria (UAE ≥300 mg/24 hours). There were 50 healthy blood donors enrolled for the control group.
All subjects were assessed for: IL-19, High-sensitivity C-reactive protein (Hs-CRP), Cystatin C, urinary albumin excretion rate (UAE) and glycosylated hemoglobin A1C (HbA1c). IL-19 was determined by the enzyme-linked immunosorbent assay (ELISA) kits. Urinary albumin and Hs-CRP concentrations were assessed using the particle enhanced immuoturbidimetric method. HbA1c was measured by liquid chromatography. Fasting plasma glucose (FPG), total cholesterol (TC), high-density lipoprotein (HDL-C) and LDL cholesterol (LDL-C) were measured by enzymatically.
The team found that the serum IL-19 levels in DN patients were found to be significantly higher compared to controls. IL-19 levels were significantly positively correlated with Hs-CRP, Cystatin C, UAE and HbA1c. In multivariable logistic regression analysis, IL-19 levels (95% CI, 20.1 to 62.9) alone showed a significant positive association with DN even after adjusting for age, gender, hypertension, and blood fat. The HbA1c in the microalbuminuric/macroalbuminuric diabetic group were significantly increased compared to normoalbuminuric and control groups.
The authors concluded that that IL-19 levels was significantly elevated in the patients with diabetic nephropathy and was associated with Hs-CRP, Cystatin C, UAE and HbA1c. The results suggest that IL-19 has an important role in the acceleration of glomerular injury in addition to its inflammatory effect on this pathophysiology, and provide further insights into the understanding of IL-19 as the possible effectiveness of anti-inflammatory therapy for DN treatment and prevention. The study was published on February 15, 2017, in the journal BMC Nephrology.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms